Zhitong Financial App News, Corning Jerry Pharmaceutical-B (09966.HK) announced that JSKN033 (a high-concentration subcutaneous combination preparation composed of human epidermal growth factor receptor 2 (HER2) bispecific antibody conjugate drug (ADC (s)) and a programmed death ligand 1 (PD-L1) immune checkpoint inhibitor) monotherapy treats recurrent or metastatic cervical cancer that failed to be treated with platinum-containing chemotherapy and PD-1/PD-L1 inhibitors (regardless of HER2 and PD-L1 expression levels) Clinical Study (Study ID: (JSKN033-301) The first patient administration has been successfully completed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.